Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06563791
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-06
Brief Title:
Assessment of the Association Between Visceral Obesity and the Progression of Diabetic Nephropathy
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Assessment of the Association Between Visceral Obesity and the Progression of Diabetic Nephropathy
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Assessment of the association between visceral obesity and the progression of diabetic nephropathy
Detailed Description:
Type 2 diabetes mellitus is a disorder of diverse aetiology characterised by hyperglycemia resulting from abnormalities of insulin action insulin production or both and the global population with diabetes mellitus is expected to be around 439 million by 2030 Diabetic nephropathy is the most prevalent microvascular consequence of DM It develops in around 40 of DM patients
Obesity which has now reached pandemic ratios is frequently accompanied by diabetes mellitus type 2 because they share common pathophysiological pathways Abdominal obesity is found to be a negligent form of obesity with dangerous consequences It has been identified as potentially hazardous factor for diabetic complications Several abdominal obesity measures have been developed including the visceral adiposity index VAI lipid accumulation product LAP neck circumference NC waist-to-hip ratio WHR Lipid accumulation product LAP and visceral adiposity index VAI are new non-imaging indicators of visceral adiposity measured using body mass index BMI waist circumference WC and serum lipid profile It was predicted in some studies that LAP and VAI have a stronger association with poor renal outcomes than BMI and WC
Obesity which has now reached pandemic ratios is frequently accompanied by diabetes mellitus type 2 because they share common pathophysiological pathways Abdominal obesity is found to be a negligent form of obesity with dangerous consequences It has been identified as potentially hazardous factor for diabetic complications Several abdominal obesity measures have been developed including the visceral adiposity index VAI lipid accumulation product LAP neck circumference NC waist-to-hip ratio WHR Lipid accumulation product LAP and visceral adiposity index VAI are new non-imaging indicators of visceral adiposity measured using body mass index BMI waist circumference WC and serum lipid profile It was predicted in some studies that LAP and VAI have a stronger association with poor renal outcomes than BMI and WC
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None